PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Published:2021-04-22 Issue:4 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Taylor Amelia M¹,Chan David Lok Hang¹²,Tio Martin¹,Patil Sujata M³,Traina Tiffany A⁴,Robson Mark E⁴,Khasraw Mustafa⁵

Affiliation:

1. Medical Oncology; Royal North Shore Hospital; Sydney Australia

2. Faculty of Medicine and Health, Northern Clinical School; University of Sydney; Sydney Australia

3. Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY USA

4. Department of Medicine; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College; New York NY USA

5. NHMRC Clinical Trials Centre, The University of Sydney; Camperdown Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference80 articles.

1. A phase III, randomized, open-label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2-negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study);Balmana;Cancer Research,2016

2. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer;Diéras;Cancer Research,2017

3. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study;Han;Annals of Oncology,2018

4. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study;Han;Cancer Research,2017

5. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale;Isakoff;Future Oncology,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden;PharmacoEconomics - Open;2023-12-13

2. Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population;Frontiers in Pharmacology;2023-11-23

3. Management of breast cancer patients with BRCA gene mutations in Jordan: perspectives and challenges;Hospital Practice;2023-08-08

4. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook;Pharmaceutics;2023-06-23

5. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023;Breast Care;2023